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 LETTER TO THE EDITOR
Serratia spp. Infection Following Breast Reconstruction
with Expanders and Implants
Dear Editor:
Serratia marcescens is a gram-negative rod in the
family “Enterobacteriaceae”, well known in the
medical fraternity to cause nosocomial infections,
particularly in moist environment results such as
tracheostomy tubes and the urinary tract. Association
of Serratia infection with breast implants is uncom-
mon. Our Serratia spp (species). infections prompted
us to identify cases in the literature of implant infec-
tion with Serratia spp. and to review the role of anti-
biotic prophylaxis prior to breast prosthesis insertion.
Between 2007 and 2011, our oncoplastic breast recon-
struction service experienced four infectious complica-
tions with S. marcescens following the insertion of
expanders. Microbiological parameters were consis-
tent, with all exhibiting resistance to cephalexin,
ceftriaxone, and augmentin, and sensitivity to genta-
micin. All cases were treated with implant removal
and saline lavage, gentamicin and betadine washout,
and intravenous gentamicin and cephalexin. New
expander placement 1 week later resulted in no
further complications.
The literature contains a report of Serratia spp.
infection following breast expander insertion as early
as 1989, describing contamination, poor hygiene, and
nonadherence to aseptic principles as the instigating
factors (1). Following an epidemiological investiga-
tion, S. marcescens was cultured from a bag of com-
mercial saline used as the source of expander fluid
and was resistant to cefazolin and cefadroxil. Chen
et al., in 1996, highlighted further the pathogenicity
of Serratia in saline-filled implants (2). Of all the
pathogens studied, only S. marcescens was able to
survive in vivo within saline breast implants placed on
the dosum of a white rabbit proliferating 80 fold in
7 days (2). Nahabedian et al.’s review of 168 recon-
structions with expanders and implants reported a
case of delayed S. marcescens infection (day 89) (3).
In a retrospective review by Mukhtar et al. (2009),
49% of breast isolates were attributable to gram-nega-
tive bacteria, with 1 case (2%) of S. marcescens (4). A
significant proportion were resistant to cefazolin, and
they suggested a range of options such as ceftriaxone/
vancomycin/clindamycin plus gentamicin for added
gram-negative cover. S. marcescens impact in surgical
site infections (SSI) is amplified as it is known to be
resistant to low concentrations of chlorhexadine solu-
tion (5). Mutation confers multidrug resistance as a
result of chromosomal b-lactamase possession and
outer membrane protein alterations, making it imper-
vious to quinolones and resistant to ampicillin, cepha-
losporins, and macrolides.
The use of antimicrobial prophylaxis against (SSI)
is widespread in plastic surgery, but results from
prospective randomized controlled trials in antibiotic
use are lacking (6). SSI prophylaxis with one preoper-
ative dose of an intravenously administered antibiotic
with antistaphylococcal activity before breast and axil-
lary surgery has been the standard care for many years
(7), and a recent review of current antibiotic prophy-
laxis among plastic surgeons favoured the use of intra-
venous cefazolin in 97% of cases (8). Brand reported
the results of 54, 661 implant procedures by 73
cosmetic surgeons with most routinely administering
systemic cephalosporin for a week (9).
Notably, there is little evidence supporting the use
of postoperative prophylactic antibiotics following
breast reconstruction surgery in reducing the postoper-
ative SSI rate. A recent retrospective review of 353
breast surgery patients revealed no statistical difference
in infection rates between patients who received preop-
erative antibiotics alone and patients with both pre
and postoperative prophylactic antibiotics (8.7%
versus 7.4% p = 0.67, respectively) (7). As an exten-
sion to the use of antibiotic prophylaxis when having a
breast implant inserted (10), some clinicians have pro-
posed incorporation of an antibiotic in the expander
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fluid (11). Cefalotin and gentamicin placed within the
lumen of inflatable breast implants in vitro have been
shown to diffuse outward through the silicone shell,
and in vivo has been shown to significantly reduce the
incidence of capsular contracture after both primary
breast augmentation and secondary open capsulotomy
(12), but further clinical trials are required before sys-
tematic recommendations can be made, particularly in
terms of the possible acquisition of resistance (13).
Despite the relatively low reported incidence of
Serratia spp. infection in the setting of breast
implants, its pathogenicity and its resistance profile
suggests the need to consider it while devising
antibiotic prophylaxis protocols, and supports the use
of gentamicin washout and intravenous administration
prior to implant insertion.
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